Key result
Lixisenatide shows no benefit over usual care for major cardiovascular events after acute coronary syndrome.
Why the study?
Does lixisenatide reduce major cardiovascular events in patients with type 2 diabetes and a recent acute coronary syndrome?
Does lixisenatide reduce major cardiovascular events in patients with type 2 diabetes and a recent acute coronary syndrome?
In patients with type 2 diabetes and recent acute coronary syndrome, adding lixisenatide to usual care does not significantly reduce major cardiovascular events.
Answers are grounded in this paper and cite their sources.
Lixisenatide adds no cardiovascular protection after acute coronary syndrome in type 2 diabetes; confirms neutral primary outcome for this GLP-1 receptor agonist.
In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events. (Funded by Sanofi; ELIXA ClinicalTrials.gov number, NCT01147250.).
No takes yet. Share an insight, caveat, or question.
Pfeffer et al. (2015) studied this question. Lixisenatide added to usual care did not significantly alter the rate of major cardiovascular events or serious adverse events in patients with type 2 diabetes and recent acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: